NEW YORK, Nov. 9, 2016 /PRNewswire/ -- Research carried out by LBT Innovations' Scientific Advisor, John Glasson, has been published in the American Society for Microbiology's prestigious Journal of Clinical Microbiology (1).
Mr Glasson and his co-authors studied the variation between human and instrument readings of microbiology culture plates during extensive trials of LBT Innovations' Automated Plate Assessment System (APAS®) image analysis device.
Mr Glasson said, "During our recent clinical trial of almost 10,000 cases, we found that members of panels of microbiologists reached agreement 96.4% of the time on the final interpretation of a culture. Yet in the same study, we found that APAS® was able to show 97.4% accuracy with the same samples."
This finding is a significant contribution to the global literature because, before its publication, there was little information on the variable interpretations made by microbiologists when reading cultures. Microbiologists were seen to always provide the correct or "gold standard" result for comparative purposes.
"Our conclusion is that humans, by their nature, produce variable results while automation such as APAS® is more objective and consistent. These factors should be considered by regulatory bodies when assessing new technologies," said Mr Glasson.
LBT Innovations' CEO and Managing Director, Brent Barnes, congratulated Mr Glasson on having his research published in a journal which is held in high regard throughout the global microbiology community.
"Our extensive trials on the APAS® technology validated our unique image interpretation software and played an important part in securing approval from the US Food & Drug Administration for APAS®," Mr Barnes said.
"We are pleased that it may have also contained important lessons for the future about how heavily we should rely on human inputs when evaluating new technologies."
(1) Glasson JH, Hill R, Summerford M, Giglio S. 2016. Observations on variations in manual reading of cultures. Journal of Clinical Microbiology 54: 2841.
About LBT Innovations
LBT Innovations (LBT) improve patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and Automated Plate Assessment System (APAS®). Based on LBT's intelligent imaging and interpretative software, APAS® specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich AG Switzerland to drive the commercialisation of APAS® products. LBT also has a third product in early development, WoundVue®, a proposed automated solution to assist in the management of chronic wounds.
For more information, see www.lbtinnovations.com
This message and its attachments may contain legally privileged or confidential information. It is intended solely for the named addressee. If you are not the addressee indicated in this message (or responsible for delivery of the message to the addressee), you may not copy or deliver this message or its attachments to anyone. Rather, you should permanently delete this message and its attachments and kindly notify the sender by reply e-mail. No warranty is made that the e-mail or attachment(s) are free from computer virus or other defect.
If you wish to be removed from our contact list please send an email to email@example.com immediately.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-lbt-research-published-in-asms-journal-of-clinical-microbiology-300359497.html
SOURCE LBT Innovations